Biomarkers in triple-negative breast cancer: State-of-the-art and future perspectives

Stefania Cocco, Michela Piezzo, Alessandra Calabrese, Daniela Cianniello, Roberta Caputo, Vincenzo Di Lauro, Giuseppina Fusco, Germira Di Gioia, Marina Licenziato, Michelino de Laurentiis

Research output: Contribution to journalReview article


Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors characterized by aggressive behavior, high risk of distant recurrence, and poor survival. Chemotherapy is still the main therapeutic approach for this subgroup of patients, therefore, progress in the treatment of TNBC remains an important challenge. Data derived from molecular technologies have identified TNBCs with different gene expression and mutation profiles that may help developing targeted therapies. So far, however, only a few of these have shown to improve the prognosis and outcomes of TNBC patients. Robust predictive biomarkers to accelerate clinical progress are needed. Herein, we review prognostic and predictive biomarkers in TNBC, discuss the current evidence supporting their use, and look at the future of this research field.

Original languageEnglish
Article number4579
Pages (from-to)1-33
Number of pages33
JournalInternational Journal of Molecular Sciences
Issue number13
Publication statusPublished - Jul 2020


  • BRCA1/2
  • CSC
  • CTCs
  • HRR
  • PDL1
  • PI3KCA
  • PTEN
  • TILs
  • TNBC

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Fingerprint Dive into the research topics of 'Biomarkers in triple-negative breast cancer: State-of-the-art and future perspectives'. Together they form a unique fingerprint.

  • Cite this